Incidence Rates of Adverse Events (CTCAE Severity ≥3) During HER2-Directed Breast Cancer Treatment Assessing the Impact of App-Based Electronic Patient-Reported Outcomes in the Randomized Controlled PRO2 Trial.
Overview & Synopsis
Open access biomedical research article published in Curr Oncol.
Indexed from repository: PubMed Central
(
pmc.ncbi.nlm.nih.gov)
Keyboard Shortcuts:
← / → for pages • + / - for zoom • 0 to fit width
Powered by Mozilla PDF.js v3.11
Document Information
| Document Title | Incidence Rates of Adverse Events (CTCAE Severity ≥3) During HER2-Directed Breast Cancer Treatment Assessing the Impact of App-Based Electronic Patient-Reported Outcomes in the Randomized Controlled PRO2 Trial. |
|---|---|
| Author / Organization | Trojan A, van Mackelenbergh M, Brucker C, Forstbauer H, Thiel M, Kolberg HC, Welslau M, Kreiss-Sender J, Dröse S, Roth S, Raeth P, Vetter M, Blum D, Fasching PA |
| Subject & Discipline | Curr Oncol |
| Categories | Medicine & Health |
| Publication Year | 2026 |
| License / Rights | Open Access / Creative Commons |
| Resource Verification | Listed PDF (Verification Pending) |
| Original Host Website |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| File Format | application/pdf (Portable Document Format) |
| Language | EN |
| Catalog ID | DOC-133965 |
| Original Source Link | Visit Source Page on pmc.ncbi.nlm.nih.gov » |